Kalaris Therapeutics, Inc.
KLRS
$5.54
$0.071.28%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 09/30/2024 | ||
|---|---|---|---|---|---|
| Net Income | -11.89M | -11.35M | -10.20M | -38.08M | |
| Total Depreciation and Amortization | 3.00K | -- | -- | -- | |
| Total Amortization of Deferred Charges | 0.00 | 0.00 | 186.00K | 0.00 | |
| Total Other Non-Cash Items | 567.00K | 591.00K | 223.00K | 32.57M | |
| Change in Net Operating Assets | -9.00K | -1.78M | 2.35M | 1.19M | |
| Cash from Operations | -11.33M | -12.54M | -7.44M | -4.33M | |
| Capital Expenditure | -183.00K | -- | -- | -- | |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | |
| Cash Acquisitions | -- | -- | -- | -- | |
| Divestitures | -- | -- | -- | -- | |
| Other Investing Activities | -34.52M | -- | -- | -- | |
| Cash from Investing | -34.71M | -- | -- | -- | |
| Total Debt Issued | 0.00 | 0.00 | 7.50M | 0.00 | |
| Total Debt Repaid | -- | -- | -- | -- | |
| Issuance of Common Stock | -- | -- | -- | 1.00K | |
| Repurchase of Common Stock | -- | -- | -- | -- | |
| Issuance of Preferred Stock | -- | -- | -- | 0.00 | |
| Repurchase of Preferred Stock | -- | -- | -- | -- | |
| Total Dividends Paid | -- | -- | -- | -- | |
| Other Financing Activities | 0.00 | 0.00 | 99.77M | 0.00 | |
| Cash from Financing | 0.00 | 0.00 | 107.27M | 1.00K | |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | |
| Net Change in Cash | -46.04M | -12.54M | 99.83M | -4.33M | |